201 E. FIFTH STREET, CINCINNATI, OH
Announces 1-for-10 Reverse Stock Split
Reports Q1 2026 Progress at Proteomedix, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix, Inc. Holds Special Meeting; Approves Reverse Stock Split Proposal
Director Resignations - Andrew Oakley and Thomas Meier Step Down
Amended material disclosure
David White Appointed Chief Executive Officer of Onconetix, Inc.
To Acquire LLC, USA-based, AI-Powered Humanoid Robotics Company
Onconetix, Inc. Holds Special Meeting; Reverse Stock Split Proposal Voted
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Late Filing for Annual Report
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
PRE 14A
PRER14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence